Study of AXT-1003 in Subjects With Advanced Malignant Tumors.

Официальное название

An Open-label, Multicenter, Phase I Safety Study of AXT-1003 in Subjects With Advanced Malignant Tumors

Обзор

This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.

Подробное описание

AXT1003-1102 is a multicenter, open-label, Phase I safety study of AXT-1003 in patients with advanced malignancies. It is designed to observe the safety of AXT-1003 in patients with advanced malignancies, determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), evaluate the pharmacokinetic profile, and explore the preliminary antitumor activity.

Вмешательства

• Препарат AXT-1003
  AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.

Первичные конечные точки

• Number of Participants With Dose-Limiting Toxicity (DLT) (Dose Escalation) [Срок оценки: Up to 28 days]
• Number of Participants with Adverse Events (AEs) [Срок оценки: Baseline up to 30 days after the last dose of study]

Вторичные конечные точки (11)

• Overall response rates (ORR) [Срок оценки: Up to 3 years]
• Duration of response(DOR) [Срок оценки: Up to 3 years]
• Progression free survival (PFS) [Срок оценки: Up to 3 years]
• Time to response (TTR) [Срок оценки: Up to 3 years]
• Disease control rate (DCR) [Срок оценки: Up to 3 years]
• Maximum observed concentration (Cmax) of AXT-1003 [Срок оценки: Up to 15 days]
• Time of maximum observed concentration (tmax) of AXT-1003 [Срок оценки: Up to 15 days]
• Area under the curve from the time of dosing to the time of the last measurable concentration (AUCtau) of AXT-1003 [Срок оценки: Up to 15 days]
• Minimum observed concentration (Cmin) of AXT-1003 [Срок оценки: Up to 15 days]
• Terminal elimination half-life (t1/2) of AXT-1003 [Срок оценки: Up to 15 days]
• Total body clearance (CL/F) of AXT-1003 [Срок оценки: Up to 15 days]

Критерии участия

Критерии включения

• For Ia dose escalation part only:

R/R NHL: Locally histopathological diagnosis of relapsed/refractory non-Hodgkin lymphoma (R/R NHL), who have progressed or been intolerant after the available standard therapies, or have no access to the standard therapies.

Advanced solid tumors: Locally histopathological diagnosis of locally advanced unresectable and metastatic solid tumors,The above subjects have progressed or been intolerant after the available standard therapies, or have no access to the standard therapies.

For Ib dose expansion part only: Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL)

• Eastern Cooperative Oncology Group (ECOG) performance status scale 0 to 1.
• Have a life expectancy of at least 3 months.
• For Ib dose expansion part and not mandatory for Ia dose escalation part: Subjects with R/R NHL must have measurable lesions as defined by Lugano 2014 criteria. Subjects with advanced solid tumors must have measurable or evaluable lesions as defined by RECIST 1.1.
• Adequate organ and bone marrow functions.
• The adequate washout period for prior therapy .
• Subjects must use a highly effective contraception method throughout the study and for 3 months after discontinuation of the study drug.
• Signed ICF and willing to comply with all the requirements in the protocol.

Критерии исключения

• Diagnosis of precursor B-cell lymphoblastic leukemia/lymphoma, precursor T-cell lymphoblastic leukemia/lymphoma, precursor NK cell lymphoblastic leukemia/lymphoma. Diagnosis of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL).
• Central nervous system infiltration.
• Uncontrolled or significant cardiovascular disease.
• Major surgery within 4 weeks before the first dose of study drug.
• Known or suspected hypersensitivity to AXT-1003 or any of the excipients.
• Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of AXT-1003.
• History of other malignancies prior to enrollment; except for subjects with basal cell carcinoma of skin, squamous cell carcinoma of skin, cervical carcinoma in situ, or other carcinomas in situ who have undergone possible curative treatment and do not have disease recurrence within 5 years since starting the treatment.
• Any prior treatment-related clinically significant toxicities that have not resolved to Grade ≤ 1 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment.
• Active infection requiring systemic treatment.
• Infection with hepatitis B virus with positive hepatitis B surface antigen, or hepatitis C virus with detectable anti-hepatitis C circulating viral RNA.
• Subjects known to be infected with human immunodeficiency virus and active tuberculosis.
• Females who are pregnant or breastfeeding.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 5 центров

• Beijing Cancer Hospital — Пекин
• Hunan Cancer Hosptial — Чанша
• Fujian Cancer Hospital — Фучжоу
• Sun Yat-Sen University Cancer Center — Гуанчжоу
• Fudan University Shanghai Cancer Center — Шанхай

Идентификаторы

NCT: NCT06484985 · AXT1003-1102

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗